EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma

Surbhi Sidana iD, Krina K Patel iD, Lauren C Peres, Radhika Bansal iD, Mehmet H Kocoglu iD, Leyla Shune, Shebli Atrash iD, Kinaya Smith, Shonali Midha, Christopher Ferreri, Binod Dhakal iD, Danai Dima iD und 26 weitere

Blood · 02.01.2025 · 145 (1) · 85-97

DOI: 10.1182/blood.2024025945 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Blood, erschienen am 02.01.2025. Verfasst von Surbhi Sidana und 37 weiteren Autor:innen. Beteiligte Einrichtung: Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Palo Alto, CA. Hauptthemen laut MEDLINE: Multiple Myeloma, Immunotherapy, Adoptive, Standard of Care. Die Arbeit wurde bisher 163-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ciltacabtagene autoleucel (cilta-cel) was approved in 2022 for patients with relapsed/refractory multiple myeloma (RRMM). We report outcomes with cilta-cel in the standard-of-care setting. Patients with RRMM who underwent leukapheresis for cilta-cel manufacturing between 1 March 2022 and 31 December 2022 at 16 US academic medical centers were included. Overall, 255 patients underwent leukapheresis and 236 (92.5%) received cilta-cel, of which 54% would not have met CARTITUDE-1 eligibility criteria. In treated patients (N = 236), cytokine release syndrome was seen in 75% (grade ≥3, 5%), immune effector cell–associated neurotoxicity syndrome in 14% (grade ≥3, 4%), and delayed neurotoxicity in 10%. Overall and complete response rates were as follows: all patients who received cilta-cel (N = 236), 89% and 70%; patients receiving conforming cilta-cel (n = 191), 94% and 74%; and conforming cilta-cel with fludarabine/cyclophosphamide lymphodepletion (n = 152), 95% and 76%, respectively. Nonrelapse mortality was 10%, most commonly from infection. After a median follow-up of 13 months from cilta-cel, the median progression-free survival (PFS) was not reached, with 12-month estimate being 68% (95% confidence interval, 62-74). High ferritin levels, high-risk cytogenetics, and extramedullary disease were independently associated with inferior PFS, with a signal for prior B-cell maturation antigen–targeted therapy (P = .08). Second primary malignancies excluding nonmelanoma skin cancers were seen in 5.5% and myeloid malignancies/acute leukemia in 1.7%. We observed a favorable efficacy profile of standard-of-care cilta-cel in RRMM, despite more than half the patients not meeting the CARTITUDE-1 eligibility criteria.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaImmunotherapy, AdoptiveStandard of CareHumansMaleFemaleMiddle AgedAgedAdultAged, 80 and overLeukapheresisBiological ProductsAntigens, CD19Cytokine Release SyndromeTreatment Outcome

Substanzen

Biological ProductsAntigens, CD19axicabtagene ciloleucel

Autor:innen und Institutionen

  • Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Palo Alto, CA.
  • Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Division of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL.
  • Division of Hematology, Mayo Clinic, Rochester, MN.
  • Division of Hematology/Oncology, University of Maryland School of Medicine, Baltimore, MD.
  • Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Medical Center, Westwood, KS.

ORCID-Profile: Surbhi Sidana, Krina K Patel, Radhika Bansal, Mehmet H Kocoglu, Shebli Atrash, Binod Dhakal, Danai Dima, Charlotte Wagner, Djordje Atanackovic, Saurabh Chhabra, Ricardo Parrondo, Hashim Mann, Ciara L Freeman, Megan Herr, Joseph McGuirk, Douglas W Sborov, Jack Khouri

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Sidana, S., Patel, K. K., Peres, L. C., Bansal, R., Kocoglu, M. H., Shune, L., Atrash, S., Smith, K., Midha, S., Ferreri, C., Dhakal, B., Dima, D., Costello, P., Wagner, C., Reshef, R., Hosoya, H., Mikkilineni, L., Atanackovic, D., Chhabra, S., …, & Hansen, D. K. (2025). Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma. Blood, 145(1), 85-97. https://doi.org/10.1182/blood.2024025945

Vancouver

Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, et al. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma. Blood. 2025;145(1):85-97. doi:10.1182/blood.2024025945

BibTeX
@article{Sidana2025,
  author = {Sidana, Surbhi and Patel, Krina K and Peres, Lauren C and Bansal, Radhika and Kocoglu, Mehmet H and Shune, Leyla and Atrash, Shebli and Smith, Kinaya and Midha, Shonali and Ferreri, Christopher and Dhakal, Binod and Dima, Danai and Costello, Patrick and Wagner, Charlotte and Reshef, Ran and Hosoya, Hitomi and Mikkilineni, Lekha and Atanackovic, Djordje and Chhabra, Saurabh and Parrondo, Ricardo and Nadeem, Omar and Mann, Hashim and Kalariya, Nilesh and Hovanky, Vanna and De Avila, Gabriel and Freeman, Ciara L and Locke, Frederick L and Alsina, Melissa and Wong, Sandy and Herr, Megan and Htut, Myo and McGuirk, Joseph and Sborov, Douglas W and Khouri, Jack and Martin, Thomas and Janakiram, Murali and Lin, Yi and Hansen, Doris K},
  title = {Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma},
  journal = {Blood},
  year = {2025},
  volume = {145},
  number = {1},
  pages = {85--97},
  doi = {10.1182/blood.2024025945}
}
Kostenlos starten →